Enteral Feeding of Premature Babies and Olive Oil Supplementation
Primary Purpose
Premature, Olive Oil, Enteral Feeding
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Extra virgin organic olive oil (ULTRA PREMIUM)
Sponsored by

About this trial
This is an interventional supportive care trial for Premature
Eligibility Criteria
Inclusion Criteria: Premature babies born at 32 weeks or less Babies who tolerate full enteral feeding at the before end of the second week Babies given consent by their parents - Exclusion Criteria: Having a congenital or genetic anomaly
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
Olive oil group
Control group
Arm Description
Babies who have fully enteral feeding will take oral, 1 ml/kg/day of extra virgin olive-oil
Outcomes
Primary Outcome Measures
Number of patients who completed the study
To enrolment of 40 babies in the study in both groups
Postnatal growth retardation rates
Daily weight intake amounts of babies in both groups
Secondary Outcome Measures
Frequency and severity of retinopathy of prematurity
Frequency and severity of retinopathy of prematurity
Full Information
NCT ID
NCT06072625
First Posted
September 13, 2023
Last Updated
October 2, 2023
Sponsor
Bursa City Hospital
1. Study Identification
Unique Protocol Identification Number
NCT06072625
Brief Title
Enteral Feeding of Premature Babies and Olive Oil Supplementation
Official Title
The Effect of Enteral Organic Extra Virgin Olive Oil Supplementation in Premature Babies on Postnatal Growth and Premature Morbidities
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 1, 2023 (Anticipated)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
March 31, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Bursa City Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
It is a two-arm prospective interventional study. 40 babies in both groups will be enrolment in the study. In the intervention group, babies will take 1 ml/kg/day of the study product (ULTRA PREMIUM) after full enteral feeding.
Supplementation will continue until discharge or the 36th week. Blood samples will be taken for serum Total antioxidant capacity and Malondialdehyde levels before the intervention and on the 14th day of the control group. At the end of the study, serum will be taken again for control values.
Daily lipid intake amounts will be recorded through breast milk analysis. Lipid profile will be monitored weekly The growth parameters of babies will be monitored daily It will be evaluated at the end of the study in terms of ROP, BPD, and NEC. At the end of the study, the data of babies in both groups will be compared.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Premature, Olive Oil, Enteral Feeding
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
80 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Olive oil group
Arm Type
Active Comparator
Arm Description
Babies who have fully enteral feeding will take oral, 1 ml/kg/day of extra virgin olive-oil
Arm Title
Control group
Arm Type
No Intervention
Intervention Type
Dietary Supplement
Intervention Name(s)
Extra virgin organic olive oil (ULTRA PREMIUM)
Intervention Description
Babies who have fully enteral feeding will take oral, 1 ml/kg/day of extra virgin olive-oil
Primary Outcome Measure Information:
Title
Number of patients who completed the study
Description
To enrolment of 40 babies in the study in both groups
Time Frame
15 months
Title
Postnatal growth retardation rates
Description
Daily weight intake amounts of babies in both groups
Time Frame
18 months
Secondary Outcome Measure Information:
Title
Frequency and severity of retinopathy of prematurity
Description
Frequency and severity of retinopathy of prematurity
Time Frame
18 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
14 Days
Maximum Age & Unit of Time
40 Days
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Premature babies born at 32 weeks or less
Babies who tolerate full enteral feeding at the before end of the second week
Babies given consent by their parents -
Exclusion Criteria:
Having a congenital or genetic anomaly
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ayten Erdoğan Ordu, MD
Phone
+905389429336
Email
aytenli21@hotmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Murat Tutanc, Prof
Phone
+905553803484
Email
drtutanc@hotmail.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Enteral Feeding of Premature Babies and Olive Oil Supplementation
We'll reach out to this number within 24 hrs